Julian Flanagan

Mx. Julian Flanagan

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
AJAndzoa N Jamus
Andzoa N Jamus
ZWZoe Elizabeth-Rifon Wilton
Zoe Elizabeth-Rifon Wilton
SASamantha D. Armijo
Samantha D. Armijo
JFJulian Flanagan
Julian Flanagan
IRIsabella Romano
Isabella Romano
KFKathryn Frietze
Kathryn Frietze
Background/Objectives: Intramuscular immunization elicits systemic IgG and is the primary route of vaccine administration in humans. However, there is growing interest in utilizing other routes of administration to tailor antibody profiles, increase immunity at primary sites of infection, simplify administration, and eliminate needle waste. Here, we investigated the antibody profiles elicited by immunization with bacteriophage virus-like particle vaccine platforms at various routes of administration. Methods: We chose two model bacteriophage vaccines for investigation: bacteriophage MS2 virus-like particles (VLPs) recombinantly displaying a short, conserved peptide from Chlamydia trachomatis major outer membrane protein (MS2) and bacteriophage Qβ VLPs displaying oxycodone through chemical conjugation (Qβ). We comprehensively characterized the antibodies elicited systemically and at various mucosal sites when the vaccines were administered intramuscularly, intranasally or periocularly with or without an intramuscular prime using various prime/boost schemes. Results: Intranasal and periocular immunization elicited robust mucosal and systemic IgA responses for both MS2 and Qβ. The intramuscular prime followed by intranasal or periocular boosts elicited broad antibody responses, and increased antibodies titers at certain anatomical sites. Conclusions: These findings demonstrate the tractability of bacteriophage VLP-based vaccines in generating specific antibody profiles based on the prime–boost regimen and route of administration.

25 February 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
ACAmanda L. Collar
Amanda L. Collar
AJAndzoa N Jamus
Andzoa N Jamus
JFJulian Flanagan
Julian Flanagan
SCSusan B. Core
Susan B. Core
WGWilliam Geisler
William Geisler
KFKathryn Frietze
Kathryn Frietze
Background/Objectives: Chlamydia trachomatis (Ct) is a common pathogen causing urogenital, anal, oral, and ocular infections. Although extensive vaccine efforts have been underway for decades, there is no licensed vaccine available to prevent human Ct infection. Polymorphic membrane protein D (PmpD) is a highly conserved protein present on the surface of Ct elementary bodies, suggesting an important role Ct biology. Repetitive tetrapeptide motifs GGA(I,L,V) and FxxN are conserved across Pmps and are important for adhesion in the related Chlamydia pneumoniae Pmp21. Methods: Using bioinformatics approaches, we identified amino acids 270 to 294 of PmpD that included two GGA(I,L,V) motifs and an FxxN motif as vaccine targets. Synthetic peptides corresponding to these regions were chemically conjugated separately via the carboxy (C)- or amino (N)-terminus (FxxN 1.1 and FxxN 1.2) to the surface of Qβ virus-like particles (VLPs) and were tested for immunogenicity and protective capacity in mice. Results: Female mice immunized three times with a mixture of Qβ-FxxN 1.1 and Qβ-FxxN 1.2 vaccines without exogenous adjuvant elicited geometric-mean endpoint dilution titers near 104. Further, mice showed decreased infection at early time points when challenged vaginally with luciferase-expressing Chlamydia muridarum over 9 days and a faster time to undetectable infection compared to controls. Immunization with individual vaccines (Qβ-FxxN 1.1 or Qβ-FxxN 1.2) did not show the same degree of reduction. Conclusions: Vaccination against PmpD tetrapeptide motifs is a novel and promising approach for limiting initial Chlamydia infection and warrants further investigation to characterize the mechanism of protection.

17 August 2026 in Redox Biochemistry and Chemistry
Verified
Journal Article
Open access
TKThilini Karunarathna
Thilini Karunarathna
Stephen R BakerStephen R Baker
Stephen R Baker
JFJulian Flanagan
Julian Flanagan
TSTroy A. Stich
Troy A. Stich
JTJesús Tejero
Jesús Tejero
DKDaniel B. Kim-Shapiro
Daniel B. Kim-Shapiro

29 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ECEmma S. Choi
Emma S. Choi
BFBen A. Flanagan
Ben A. Flanagan
HAHeather Alexander
Heather Alexander
JBJohn Berini
John Berini
AYAlex Yeung
Alex Yeung
AHAmanda K. Hund
Amanda K. Hund
Summary: Population-specific immunity can drive variation in infection outcomes, but studying immune variation in the wild is challenging because exposure histories are unknown. Comparing wild populations with those reared in a common environment can disentangle genetic and environmental drivers of immunity. We applied this approach in freshwater threespine stickleback, where populations vary in their use of intraperitoneal fibrosis to defend against the helminth parasite Schistocephalus solidus . We combined a 46-lake immune survey with a common garden experiment using 20 representative populations to examine variation in fibrosis and infection. Laboratory assays included exposures to live tapeworms and immune challenges with tapeworm proteins and aluminum phosphate (Alum). We found heritable variation in both constitutive fibrosis and inducible fibrosis. Inducible responses to tapeworms were associated with lake environmental conditions, with fish from more eutrophic-like lakes showing stronger fibrosis induction than those from more oligotrophic-like lakes. Together, these results show how integrating wild immune variation with common garden experiments can reveal novel heritable defenses and link their evolution to ecological variation.